Long-term persistence of antibodies after one or two doses of MMR-vaccine

Vaccine

Volumn 25, Issue 37-38, 2007, Pages 6672-6676

  Vandermeulen, Corinne ^a   Mathieu, Roelants ^a   Geert, Leroux Roels ^b   Pierre, Van Damme ^c   Karel, Hoppenbrouwers ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Antibodies; Immunization; Measles; Mumps; Rubella

Indexed keywords

ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; PRIORITY JOURNAL; RUBELLA; SEX DIFFERENCE; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MEASLES-MUMPS-RUBELLA VACCINE; TIME FACTORS;

EID: 34548235421     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.008     Document Type: Article

References (26)

1. WHO European Region. Eliminating measles and rubella and preventing congenital rubella Infection. WHO European region strategic plan 2005-2010. Available at: http://www.euro.who.int/document/E87772.pdf. Accessed 02 April 2007.
2. Siedler A., Tischer A., Mankertz A., and Santibanez S. Two outbreaks of measles in Germany 2005. Euro Surveill 11 4 (2006) 131-134
3. van Treeck U. Measles outbreak in Germany: over 1000 cases now reported in Nordrhein Westfalen. Euro Surveill 11 5 (2006) 060511. http://www.eurosurveillance.org/eq/2006/02-06/pdf/eq_5_2006_140-140.pdf [Available at http://www.eurosurveillance.org/eq/2006/02-06/pdf/eq_5_2006_140-140.pdf. Accessed April 02, 2007]
4. Georgakopoulou T., Grylli C., Kalamara E., Katerelos P., Spala G., and Panagiotopoulos T. Current measles outbreak in Greece. Euro Surveill 11 2 (2006) 060223
5. Boncompagni G., Incandela L., Bechini A., Giannini D., Cellini C., Trezzi M., et al. Measles outbreak in Grosseto, central Italy. Euro Surveill 11 8 (2006). http://www.eurosurveillance.org/ew/2006/060803.asp [Available at http://www.eurosurveillance.org/ew/2006/060803.asp#4. Accessed April 02, 2007]
6. Hamilton-West K. Factors influencing MMR vaccination decisions following a mumps outbreak on a university campus. Vaccine 24 24 (2006) 5183-5591
7. Muscat M., Hartvig Christiansen A., Persson K., Plesner A.M., Böttiger B.E., Glisman S., et al. Measles outbreak in ∅resund region of Denmark and Sweden. Euro Surveill 11 3 (2006) 060330. http://www.eurosurveillance.org/ew/2006/060330.asp [Available at http://www.eurosurveillance.org/ew/2006/060330.asp#4. Accessed April 02, 2007]
8. Torner N., Valerio L., Costa J., Parron I., and Dominguez A. Rubella outbreak in young adults of Brazilian origin in a Barcelona suburb, October-December 2005. Euro Surveill 11 2 (2006). http://www.eurosurveillance.org/ew/2006/060223.asp [Available at http://www.eurosurveillance.org/ew/2006/060223.asp#3. Accessed April 02, 2007]
9. van der Veen Y., Hahne S., Ruijs H., van Binnendijk R., Timen A., van Loon A., et al. Rubella outbreak in an unvaccinated religious community in the Netherlands leads to cases of congenital rubella syndrome. Euro Surveill 10 11 (2005). http://www.eurosurveillance.org/ew/2005/051124.asp [Available at http://www.eurosurveillance.org/ew/2005/051124.asp#3. Accessed April 02, 2007]
10. CDC. Update: multistate outbreak of mumps-United States. MMWR 55 20 (2006) 559-563 [January 1-May 2, 2006]
11. Parker A.A., Staggs W., Dayan G.H., Rota P.A., Lowe L., Boardman P., et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Eng J Med 355 5 (2006) 447-455
12. Strebel P.M., Papania M.J., and Halsey N.A. Measles vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccine. 4th ed. (2004), Saunders, Philadelphia 389-440
13. van den Hof S., Berbers G.A.M., de Melker H.E., and Conyn-van Spaendonck M.A.E. Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage. Vaccine 18 (1999) 931-940
14. Bonnet M.C., Dutta A., Weinberger C., and Plotkin S.A. Mumps vaccine virus strains and aseptic meningitis. Vaccine 24 (2006) 7037-7045
15. Vandermeulen C., Roelants M., Vermoere M., Rosseeuw K., Goubau P., and Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?. Vaccine 22 21/22 (2004) 2713-2716
16. Christenson B., and Böttiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 12 2 (1994) 129-133
17. Plotkin S.A. Mumps vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccine. 4th ed. (2004), Saunders, Philadelphia 441-469
18. Beutels Ph, Van Damme P., Van Casteren V., Gay N.J., De Schrijver K., and Meheus A. The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 20 (2002) 3551-3559
19. Lernout T. Surveillance van infectieziekten bij kinderen in België. Pedisurv. Jaarverslag 2005. IPH/EpiReports nr 2006-024.
20. Committee for the elimination of measles and rubella in Belgium. Eliminatie van rubella in België. Amendement van het eliminatieplan voor mazelen in België. Available at http://www.iph.fgov.be/epidemio/epinl/plabnl/rubella.pdf. Accessed on 14 May 2007.
21. Orenstein W.A., Hinman A.R., and Strebel P.J. Measles: the need for 2 opportunities for prevention. Clin Infect Dis 42 (2006) 320-321
22. LeBaron C.W., Beeler J., Sullivan B.J., Forghani B., Bi D., Beck C., et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 161 (2007) 294-301
23. Paunio M., Peltola H., Valle M., Davidkin I., Virtanen M., and Heinonen O.P. Twice vaccinated recipients are better protected against measles than are single dose recipients of measles containing vaccine. J Epidemiol Commun Health 53 (1999) 173-178
24. Güris D., McCready J., Watson J.C., Atkinson W.L., Heath J.L., Bellini W.J., et al. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr Infect Dis J 15 12 (1996) 1082-1086
25. Davidkin I., Peltola H., Leinikki P., and Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15 year follow-up in Finland. Vaccine 18 (2000) 3106-3112
26. Dhiman N., Ovsyannikova I.G., Ryan J.E., Jacobson R.M., Vierkant R.A., Pankratz V.S., et al. Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination. Clin Exp Immunol 142 3 (2005) 498-504